DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
29 hedge funds and large institutions have $351K invested in DMK Pharmaceuticals Corporation Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
97% more capital invested
Capital invested by funds: $179K → $351K (+$173K)
16% more funds holding
Funds holding: 25 → 29 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$60.1K |
| 2 |
JP Morgan Chase
New York
|
+$41.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
-$9.13K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$8.29K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$6.76K |
| 4 |
BlackRock
New York
|
-$461 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$69 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPG
26
Cornerstone Planning Group
Fairfield,
New Jersey
| $5 | – | – | – |
|
|
CIA
27
Cape Investment Advisory
Mcdonough,
Georgia
| $1 | – | – | – |
|
|
WAS
28
Winch Advisory Services
Appleton,
Wisconsin
| $1 | – | – | – |
|
29
Fidelity Investments
Boston,
Massachusetts
| $1 | +$1 | +1 | New |
|
|
SG
30
StoneX Group
New York
| – | -$9.13K | -13,258 | Closed |
|
|
XT
31
XTX Topco
George Town,
Cayman Islands
| – | -$8.29K | -12,024 | Closed |
|
|
32
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$69 | -100 | Closed |
|
DMK Hedge Fund Activity: Q4 2023 in Review
29 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2023, worth a combined $351K — up 97% from $179K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new DMK positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $60.1K. The largest seller was StoneX Group, exiting entirely with an estimated $9.13K sold.
- 29 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2023, up from 25 in Q3 2023.
- Funds reported $351K of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2023, up 97% quarter-over-quarter.
- 7 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2023 and 3 closed out, a net change of +4 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2023 was Northern Trust, an estimated $60.1K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2023 was StoneX Group, an estimated $9.13K sold.
Based on aggregated 13F filings for Q4 2023.